Pemafibrate significantly reduced fibrinogen levels in patients with coronary artery disease (CAD) and hypertriglyceridaemia (HTG), highlighting its primary benefit in lowering thrombotic risk, concluded researchers who carried out a multicentre, randomised, controlled trial to evaluate the effect of pemafibrate on fibrinogen levels in patients with CAD and HTG undergoing antiplatelet monotherapy and statin therapy.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
